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Background With significant developments in
the management of metastatic breast cancer, the
trajectory of progressive breast cancer is
becoming increasingly complex with little
understanding of the illness course experienced
by women, or their ongoing problems and
needs.
Aim This study set out to systematically explore
the illness trajectory of metastatic breast cancer
using models from chronic illness as a
framework.
Design Longitudinal mixed methods studies
detailing each woman’s illness trajectory were
developed by triangulating of narrative
interviews, medical and nursing documentation
and an assessment of functional ability using the
Karnofsky Scale. The Corbin and Strauss Chronic
Illness Trajectory Framework was used as a
theoretical framework for the study.
Participants Ten women aged between 40 and
78 years, with metastatic breast cancer.
Results Women’s illness trajectories from
diagnosis of metastatic disease ranged from
13 months to 5 years and 9 months. Eight of the
10 women died during the study. Chronic illness
trajectory phases identified by Corbin and Strauss
(pretrajectory, trajectory onset, living with
progressive disease, downward phase and dying
phase) were experienced by women with
metastatic breast cancer. Three typical
trajectories of different duration and intensity
were identified. Women’s lives were dominated
by the physical burden of disease and treatment
with little evidence of symptom control or
support.
Conclusions This is the first study to
systematically explore the experience of women
over time to define the metastatic breast cancer
illness trajectory and provides evidence that
current care provision is inadequate. Alternative
models of care which address women’s
increasingly complex problems are needed.
INTRODUCTION
Breast cancer has been the focus of
intense study by the scientific community
over many decades with initiatives tar-
geted at better management or fair access
to new treatments for early stage
disease.1 It is therefore surprising that so
little attention has been given to the
issues faced by women who develop
metastatic disease other than in the
context of end-of-life care.
It is estimated that in the UK, around
36 000 women are living with progres-
sive disease, with 12 000 being in the last
year of life.2 Developments in treatments
may be extending survival and improving
the management of the disease, leading
to the suggestion that breast cancer may
be becoming a chronic illness. However
as yet, little information exists as to the
course of metastatic disease, or whether
current models of palliative care services
organised around providing intensive
support at the end of life are meeting the
needs of women living with progressive
disease.
DEFINING THE ILLNESS TRAJECTORY
OF METASTATIC BREAST CANCER
The concept of ‘illness trajectory’ has
been described extensively in relation to
chronic illness and to the process of
dying.3 4 It refers to the events over the
course of illness which are shaped by the
individual’s response to illness, interac-
tions with those around them and inter-
ventions. Glaser and Strauss3 refer to the
events that unfold for an individual who is
dying as having two elements—time and
shape, and chart the relationship between
expectations of when death may occur by
professionals, family members and the
individual. The concept of trajectory
introduced by Strauss et al(ref. 5, p.66)
encompasses not only the ‘physiological
unfolding of a patient’s disease but the
total organisation of work done over the
course of illness and the impact on those
involved with that work and its organiza-
tion’ and despite the passage of time is
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still considered relevant today.6 There has been consid-
erable interest in charting the course of different dying
trajectories as a means of tailoring palliative care ser-
vices prior to death,7–10 most recently exploring the
experience of patients living through the trajectories of
specific cancers, such as glioma.11 Strauss et al5
described a Chronic Illness Trajectory Framework
where the pattern of illness is characterised by a cycle
of ‘decline-reprieve-decline-reprieve-decline to death’,
which renders expectations uncertain and arrange-
ments and plans unpredictable.
This paper reports the findings of a study that set
out to systematically explore the illness trajectory of
progressive breast cancer and to examine women’s
experiences while living with the disease.
METHODS
Two hundred and thirty-five women were recruited to
participate in a national questionnaire survey of
health-related quality-of-life and experience of care.
The results of the survey are reported elsewhere.12
This paper reports the detailed data from the cases of
10 women selected from the 235 who consented to
participate in a longitudinal study of their experiences.
Women who took part in the survey were asked to give
their contact details if they were interested in taking
part in interviews about their experience. A longitu-
dinal mixed-methods approach was adopted. Using a
primarily qualitative approach, a number of data
sources were combined to systematically chart the
illness trajectory of breast cancer from the point of
diagnosis of progressive disease until death. Ten
women were selected to represent different experi-
ences of progressive breast cancer, such as age and site
of metastatic spread, as well as those with indolent and
aggressive disease, and where there were also complete
medical and nursing records that could be accessed for
the research. The characteristics of the 10 women
chosen are described in table 1.
Women were interviewed three times over one cal-
endar year using a qualitative narrative approach.13
All interviews were conducted in the participants’
homes by one interviewer (ER). Each lasted, on
average, 60 min. Each woman was given the oppor-
tunity to withdraw from the study before each inter-
view, and support materials and contacts were made
available to all participants. Data from women’s narra-
tive interviews and documentation (including medical
notes, oncologist annotations of appointments,
nursing notes, correspondence between healthcare
professionals, investigation results) were triangulated
to map in detail the illness trajectory of each woman’s
metastatic breast cancer. Over one calendar year, eight
women were interviewed three times; two women
were interviewed twice, but died before the final
interview.
A biographic narrative interview approach13 was
adopted to explore in detail women’s experience of
living with progressive breast cancer. Narrative
inquiry differs from conventional interviewing in that
variation in responses is as important as consistency,
and diversity in the narrative is sought through a less
formal interview schedule and more of an interaction-
alist approach.14 At the first interview, the opening
question was ‘tell me about yourself ’. Subsequent
interviews began with an open question, ‘tell me what
has happened since we last spoke’. The participant,
rather than the interviewer determines the narrative
form.
Interviews were transcribed verbatim and analysed
in their entirety. A framework was developed using
Lieblich et al’s13 holistic-form and holistic-content
analysis approach. Metastories were developed for
each woman from the three interviews to build a
chronologically ordered story. Data collected from
clinical documentation were added to the metastories.
Diagrammatic representations of the illness trajectories
were then developed. Using data from medical records
and women’s narrative accounts, a retrospective esti-
mate of women’s functional ability was made from
first diagnosis of metastatic disease until the end of
data collection, or death, to develop a graphic repre-
sentation of the 10 trajectories using the Karnofsky
Scale15 (table 2). These assessments were placed
Table 1 Disease characteristics of the 10 women
Disease characteristics n (Mean)
Age range 40–78 years (54)
Disease-free survival 1–10 year (3)
Number of metastatic sites 1 site: 2 women
2 sites: 2 women
3 sites: 6 women
Time living with metastatic
disease*
13 months to 7 years 3 months
(4 years)
*One woman diagnosed with metastatic disease at first presentation.
Table 2 Karnofsky Performance Scale15
Value Level of functional capacity
10 Normal, no complaints, no evidence of disease
9 Able to carry on normal activity, minor signs or symptoms of
disease
8 Normal activity with effort, some signs or symptoms of disease
7 Cares for self, unable to carry on normal activity or to do active
work
6 Requires occasional assistance, but is able to care for most needs
5 Requires occasional assistance and frequent medical care
4 Disabled, requires special care and assistance
3 Severely disabled, hospitalisation is indicated although death is
not imminent
2 Hospitalisation is necessary, very sick, active supportive treatment
necessary
1 Moribund, fatal processes progressing rapidly
0 Dead
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alongside the women’s metastories. Key trajectory
events from the metastories were then superimposed
onto the trajectory to reflect women’s illness experi-
ence and the health system’s response to it.
Existing trajectories of dying3 4 were reviewed to
examine the ‘fit’ of these to the trajectories derived
from the metastories and were found not to reflect
the data. Instead, Corbin and Strauss’ Chronic Illness
Trajectory Model16 was felt to better explain the
experiences of women in this study and was therefore
used as a framework to describe the illness trajectory
of metastatic breast cancer (table 3).
FINDINGS
As in Corbin and Strauss’ model, five trajectory
phases were identified; the pretrajectory phase, trajec-
tory onset, living with progressive disease, downward
phase and dying phase (figure 1).
Phase 1: The pretrajectory phase of metastatic breast
cancer
Women’s narratives began by describing events before
metastatic disease was diagnosed. This included life
before their diagnosis of primary disease, and life
after completing treatment for early stage disease.
Reflecting back, women tried to identify the cause of
their disease progressing, a common theme was to
attribute this to previous life stress or lifestyle; women
felt personal responsibility for their disease
progression.
‘I just kind of thought I had to be superwoman...
and that was a really stupid thing to do and I had
three different jobs and I was doing between 50–
60 hours a week…I just couldn’t see the bigger
picture and I do think that contributed to, to sort of
the speed up of my condition I am sure.’ Dawn
Women identified other life events which they
feared as possible causes of progressive disease, such
as marital breakdown.
Phase 2: The trajectory onset—diagnosis and adjustment
to progressive disease
Most of the women experienced an insidious onset of
symptoms over time. From presenting with symptoms
to getting the diagnosis could be long and complex.
Having spent really hundreds of pounds at the chiro-
practor, various other things trying to get my back
sorted out…the pain got worse…it never really sort of
seemed to resolve and a very long story, after seeing
her [chiropractor], she said I think you should go back
to the doctor so I went to the doctor and they sent me
for an x-ray. Jill
This was of great concern to some of the women,
because of the worry that in the ensuing time their
disease would be progressing and reduce their overall
survival. Women appeared unsure how to re-enter the
healthcare system, and often took a convoluted path
before getting an appointment. Once within, there
appeared no structured pathway to ensure they
received appropriate care and support.
How the diagnosis and future was explained was
key to how women coped. When a level of hope was
given that treatment was aimed to improve symptoms
Table 3 Definitions of the Corbin and Strauss Chronic Illness Trajectory Model phasing16
Phase Goal of definition Goal of management
Pretrajectory Genetic factors or lifestyle behaviours that place an individual or community at risk for
the development of a chronic condition
Prevent onset of chronic illness
Trajectory
onset
Appearance of noticeable symptoms, includes periods of diagnostic workup and
announcement by biographical limbo as person begins to discover and cope with
implications of diagnosis
Form appropriate trajectory projection and
scheme
Stable Illness course and symptoms are under control. Biography and everyday life activities are
being managed within limitations of illness. Illness management centres in the home
Maintain stability of illness, biography and
everyday activities
Unstable Periods of inability to keep symptoms under control or reactivation of illness.
Biographical disruption and difficulty in carrying out everyday life activities. Adjustments
being made in regime with care usually taking place at home
Return to stability
Acute Severe and unrelieved symptoms or development of illness complications necessitating
hospitalisation or bed rest to bring course under control. Biography and everyday life
activities temporarily placed on hold or drastically cut back
Bring illness under control and resume normal
biography and everyday life
Crisis Critical or life-threatening situation requiring emergency treatment or care. Biography and
everyday life activities suspended until crisis passes
Removal of threat
Comeback A gradual return to an acceptable way of life within the limits imposed by disability or
illness. Involves physical healing, limitations stretched through rehabilitative procedures,
psychosocial coming to terms, and biographical re-engagement and adjustment in
everyday life
Set in motion and keep going the trajectory
projection and scheme
Downward Illness course characterised by rapid or gradual physical decline accompanied by
increasing disability or difficulty in controlling symptoms. Requires biographical
readjustment and alterations in everyday life with each major downward step
To adapt to increasing disability with each
major downward turn
Dying Final days before death. Characterised by gradual or rapid shutting down of bodily
processes, biographical disengagement and relinquishment of everyday life and activities
To bring closure, let go and die peacefully
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or extend survival time, the women felt more confi-
dent about the future. However, if the limitations of
treatment were emphasised, or a poor prognosis
given, it had a significant impact on the women’s
ability to cope and adjust to the diagnosis. The
process of adaptation and assimilation of the news of
progressive cancer for some took time and was chal-
lenged by the physical manifestations of disease and
the side effects of treatment.
By contrast with the diagnosis of primary breast
cancer, when metastatic disease was diagnosed, few
women appeared to have access to formal support ser-
vices describing their main support as family and
friends. One woman felt she had been ‘cast adrift’
with no healthcare professional to support her.
Following her diagnosis of brain metastases, Angela
felt the need for support but did not know how to
access this.
I don’t know what I expected or what sort of care
I expected; not knowing what there is to be offered
you know? Nobody’s ever offered anything or said
“oh well, we’ll visit you” or anything like that…even if
it was a little phone call to see how you are because
you feel like you’re…you’ve been told, you’ve been
diagnosed, you’re sent home and that’s it. What do
you do about it? That’s how I felt. I was just thinking
well what do I do about it? Angela
Few women had access to formal support, and the
mobilisation of support services appeared to be asso-
ciated with a physical need only.
Phase 3: Living with progressive disease
Uncertainty pervaded every element of women’s lives
during this phase of illness. The continual oscillations
between illness, treatment and recovery that women
experienced undermined their ability to adjust. Those
with more aggressive disease appeared to have little
respite from the cycle of disease progression and treat-
ment. They struggled to keep pace with changing
events which eroded their sense of self and ability to
adjust and adapt to the rapidity of events, at the same
time as coping with the present and a foreshortened
future.
For example, Jill’s illness trajectory highlighted a
life with metastatic breast cancer which was domi-
nated by sequential treatments. Over a 3-year period,
she endured nine different episodes of treatment
(bisphosphonates, radiotherapy and chemotherapy).
Jill went through cycles of feeling and looking well
and living her life to the full, followed by disease pro-
gression and illness.
Most women appeared to tolerate uncontrolled
pain, and self-medicated, supporting the findings of
our survey which found over one-third of women
(34%) reporting high levels of pain and other uncon-
trolled symptoms.12 There appeared to be little
ongoing palliation of symptoms. Angela was pre-
scribed analgesia, but tolerated uncontrolled pain for
4 years.
It is just, it is just like a, a gnawing pain and it is,
sometimes it gets you down because you think God
Figure 1 Metastatic breast cancer illness trajectory phases.
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just go away for the day and sometimes I think if only
I could have one day where I think oh I feel really
good today and it never happens, that, that is what
I think gets to you because you just feel so bad all the
time. Angela
A few of the women had involvement with palliative
care services, but only one (Mary) maintained this
relationship over time.
While treatment allowed some respite from the
symptoms of progressive disease and potentially
increased their survival time, living with a progressive
disease appeared exhausting in its relentlessness.
Once I came off the chemo there’s this sense of kind
of waiting, and there’s this sense of paranoia that I’m
kind of looking every day and feeling and prodding
and pushing and thinking “what can I feel?” “What
can I see?” “Am I OK or not?” “Am I kidding myself?”
I know that’s not the way to live, you should just kind
of embrace every day and get on with it. Dawn
All the women had times when their disease was
stable. During this time, anticipating progressive
disease meant the women lived with relentless vigi-
lance over their bodies.
Phase 4: downward phase
The downward phase of illness was characterised by
episodes of illness and crisis of increasing frequency.
Acute episodes were often a result of chemotherapy
side effects, physical deterioration, uncontrolled
symptoms, such as breathlessness and cerebral symp-
toms. Five of the women attended an accident and
emergency department during this phase.
Crisis events marked the final downward phase for
four of the women. All were admitted to hospital via
an accident and emergency department; two for
uncontrolled pain and two for neutropenic sepsis
associated with chemotherapy.
Phase 5: dying phase
Eight of the women died during the study. The events
leading to Joy’s death are unknown. Of the remaining
seven, one died peacefully at home, three died in a
hospice and three died in hospital. All those admitted
to either the hospice or hospital died within days of
admission, other than Paula who died within 2 weeks.
Of the four who had unplanned admissions leading
to their death, two had neutropenic sepsis associated
with chemotherapy. From the illness trajectories of
these women it appears that they were actively treated
up until and including the dying phase of their lives.
There was a decision to stop active treatment (chemo-
therapy) for three women.
The constant quest for the next treatment and to
prolong their lives meant few had support services in
place to help them until the end stage of their lives.
Some knew there were support services but associated
them (palliative care and the hospice movement) with
the end of life and appeared reluctant to access them.
Few had an established relationship with a palliative
care service before the last year of life, and for some
only days or weeks before death. There appeared to
be little awareness of where to seek information about
end-of-life care.
You know, no one has ever offered anything, or said
oh well we’ll visit you or anything like that. The other
concern I have got is when it comes right near the end
when I am really poorly what do I do? Do I just stay
here or do I go into hospital? Do you have to book
something? Or that sort of thing… [pause] that I
think you really don’t know. Angela
Angela asked her general practitioner (GP) to refer
her to a community palliative care team 2 years before
she died, and he told her she was not ready for that
yet, even though she had endured uncontrolled pain
and other symptoms throughout her illness trajectory.
Among the women who died, there was a rapid
decline towards the end of their lives; the end of their
lives appeared to illustrate disintegrated dying,4 where
the events were chaotic and the end of anticancer
treatment overlapped with the end of life.
Consequently, there appeared to be little preparation
for death.
At Mary’s last hospital appointment, when a CT
scan showed her disease had progressed despite the
treatment, she decided not to have any further
treatment.
The funny thing was when I walked out of the room
from seeing the specialist I felt as if the weight had
been lifted off my mind, which sounds peculiar but
I think you feel right, well you’ve done everything you
possibly can, you can’t do anymore, you know, go out
there and live your life every day. And that’s what
I plan to do. Mary
While it cannot be claimed that the role of support-
ive palliative care services and GP had an influence on
Mary dying at home, this illness trajectory was the
exception, and the support services Mary received, as
well as good social support, were almost certainly
influential in this.
TYPICAL ILLNESS TRAJECTORIES
While the issues faced by all 10 women were similar,
the course of illness was not the same for all of them.
Three typical but different illness trajectories were
identified.
Illness trajectory 1 ‘ticking over nicely’: is illustrated
by Joan (figure 2). It was typically long, spanning
years and characterised by indolent disease, often with
bone metastases, but no other sites of disease spread
for a considerable time. Physical functioning was high.
Joan was asymptomatic for the majority of the illness
trajectory, and for the most part maintained her phys-
ical functioning at a high level. She experienced two
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different endocrine treatments, and one chemotherapy
regimen.
Illness trajectory 2 ‘is there no end to it’: is illu-
strated by Paula (figure 3) and was characterised by a
short duration, with a gradual deterioration in phys-
ical functioning punctuated by episodes of disease
progression, uncontrolled symptoms, sequential treat-
ment and its side effects, with little respite. Paula had
aggressive, rapidly progressing disease.
Over the 13-month period Paula experienced three
episodes of disease progression, three different
chemotherapy regimens, one endocrine therapy and
one fraction of radiotherapy for bone pain. She was
physically compromised for the majority of time,
experiencing pain and fatigue throughout the illness
trajectory which she managed herself. She accessed no
palliative care services until an acute hospital admis-
sion for breathlessness 1 month before she died.
Illness trajectory 3 ‘it’s a rollercoaster’: is illustrated
by Shelley (figure 4). This appeared to be the most
typical illness trajectory, where the duration was
longer (2–5 years or more). Physical functioning could
decline but then recover, and at times increase to a
level higher than before an event which caused the
decline. Shelley experienced the oscillations of disease
progression, treatment and the restoration of a level
of well-being, as well as acute episodes and crises.
DISCUSSION
This study suggests that for many women with meta-
static breast cancer, cycles of decline and reprieve are
the norm over an extending lifespan. Both the
number of decline-reprieve cycles, and the time inter-
val between these, can become extended because of
the availability of a large number of new treatment
options. The consequence of this is that women’s lives
are dominated by treatment and they endure chronic
pain and symptoms that they largely manage for
themselves. Women find themselves in a complex rela-
tionship with their oncologist where cycles of treat-
ment are offered, accepted and endured as the only
option for prolonging life at whatever cost, with little
apparent planning for moments of decline resulting in
admissions to hospital and the final months of life are
characterised by disintegrated dying. Trajectories 2
and 3 could both be characterised as disintegrated
dying trajectories4 though these were experienced
over an extended period of time by women.
Trajectory 3 could be considered more of an episode
within a longer, yet to be concluded trajectory.17This
trajectory would more closely fit with Strauss et al’s5
characterisation of the chronic illness trajectory of
decline-reprieve-decline-reprieve-death.
Women are not in ‘denial’ over the seriousness of
their illness, but find themselves with their oncolo-
gists, caught in a constant bid for further illness
reprieve. Oncologists are hampered by the difficulty
in recognising when the final decline has commenced
or may occur, or that women may die from the conse-
quences of treatment itself.
The approach taken in this study of combining dif-
ferent sources of data with women’s narrative
Figure 2 Illness trajectory ‘ticking over nicely’.
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Figure 4 Illness trajectory ‘it’s a rollercoaster’.
Figure 3 Illness trajectory ‘is there no end to it?’.
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accounts of their illness experience, has proved valu-
able in identifying the pattern of metastatic breast
cancer, and could provide a means of identifying
those in most need of support. Its strengths were the
range of women’s experience, the longitudinal design
and the addition of clinical documentation. The find-
ings support our earlier survey that there is little evi-
dence of palliative care involvement with these
patients,12 and indicates that palliative care is needed
much earlier than presently provided.
The study challenges the configuration of palliative
care services that focus on the end of life, when an
increasing number of those with metastatic cancer are
considered survivors who may live for years with pro-
gressive disease. By turning to the management of
chronic illness, models of care incorporating
approaches to supported self-management policy
makers and clinicians could better address the needs
of those living over time with progressive disease.
This change may have cost benefits for healthcare pro-
vision through, for example, more appropriate use of
analgesics and anticancer treatment, and a reduction
in unnecessary hospital admissions.
Palliative care services have the expertise and
experience to improve quality of life in metastatic
disease, but the focus is currently on the end of life
which is only is a short phase of a much longer illness
trajectory, with the final decline becoming increasingly
difficult to identify. A more integrated oncology and
palliative care approach is needed to support women
and oncologists in making difficult decisions over
when to stop treatment and to plan for end of life.
CONCLUSION
This is the first study to systematically study the
events that unfold for women with metastatic breast
cancer in the context of current treatment. It suggests
that significant adjustment needs to be made to
current models of care, as these are no longer fit for
purpose given the increasingly chronic nature of the
disease.
LIMITATION
The illness trajectory of 10 women with metastatic
breast cancer may not be a true representation of all
those with metastatic breast cancer throughout the
UK.
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